MT Newswires
Tandem Diabetes Care Shares Rise After Truist Upgrade
📈
AI Sentiment
Highly Positive
8/10
- Home
- TNDM
as of 03-23-2026 3:52pm EST
$25.14
+$0.34
+1.35%
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | San Diego |
| Market Cap: | 1.4B | IPO Year: | 2013 |
| Target Price: | $28.33 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.04 | EPS Growth: | -106.80 |
| 52 Week Low/High: | $10.00 - $29.65 | Next Earning Date: | 04-29-2026 |
| Revenue: | $1,014,736,000 | Revenue Growth: | 7.93% |
| Revenue Growth (this year): | 8.01% | Revenue Growth (next year): | 12.14% |
| P/E Ratio: | -8.16 | Index: | N/A |
| Free Cash Flow: | -29669000.0 | FCF Growth: | N/A |
AI-Powered TNDM Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 21 hours ago
AI Recommendation
hold
Model Accuracy: 75.30%
75.30%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Tandem Diabetes Care Inc. (TNDM)
Novara Mark David
Sell
EVP & CHIEF COMMERCIAL OFFICER
TNDM Mar 17, 2026
Avg Cost/Share
$23.05
Shares
187
Total Value
$4,310.35
Owned After
37,656
SEC Form 4
Novara Mark David
Sell
EVP & CHIEF COMMERCIAL OFFICER
TNDM Mar 5, 2026
Avg Cost/Share
$22.81
Shares
2
Total Value
$45.62
Owned After
37,656
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Novara Mark David | TNDM | EVP & CHIEF COMMERCIAL OFFICER | Mar 17, 2026 | Sell | $23.05 | 187 | $4,310.35 | 37,656 | |
| Novara Mark David | TNDM | EVP & CHIEF COMMERCIAL OFFICER | Mar 5, 2026 | Sell | $22.81 | 2 | $45.62 | 37,656 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 19, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K BUYFeb 19, 2026 · 100% conf.
AI Prediction BUY
1D
+13.62%
$21.04
Act: +32.67%
5D
+14.20%
$21.15
Act: +39.25%
20D
+28.62%
$23.82
Price: $18.52 Prob +5D: 100% AUC: 1.000
0001438133-26-000009
tndm-202602190001438133FALSE00014381332026-02-192026-02-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026
Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3618920-4327508 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.) 12400 High Bluff Drive92130 San Diego California (Zip Code) (Address of principal executive offices)
Registrant’s telephone number, including area code: (858) 366-6900 N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of Each ClassTrading SymbolName of Each Exchange on Which Registered Common Stock, par value $0.001 per shareTNDMNASDAQ Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 19, 2026, we issued a press release reporting our financial results for the quarter and year ended December 31, 2025. This press release has been furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
The information under this Item 2.02 and Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Number Description
99.1Press release of Tandem Diabetes Care, Inc. dated February 19, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Tandem Diabetes Care, Inc.
By:/s/ SHANNON M. HANSEN Shannon M. Hansen Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary
Date: February 19, 2026 3
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
2025
Q3
Q3 2025 Earnings
8-KNov 6, 2025
0001438133-25-000186
tndm-202511060001438133FALSE00014381332025-11-062025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025
Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3618920-4327508 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.) 12400 High Bluff Drive92130 San Diego California (Zip Code) (Address of principal executive offices)
Registrant’s telephone number, including area code: (858) 366-6900 N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of Each ClassTrading SymbolName of Each Exchange on Which Registered Common Stock, par value $0.001 per shareTNDMNASDAQ Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 6, 2025, we issued a press release reporting our financial results for the quarter ended September 30, 2025. This press release has been furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
The information under this Item 2.02 and Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Number Description
99.1Press release of Tandem Diabetes Care, Inc. dated September 30, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Tandem Diabetes Care, Inc.
By:/s/ SHANNON M. HANSEN Shannon M. Hansen Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary
Date: November 6, 2025 3
2025 Q2 Q2 2025 Earnings
8-K Aug 6, 2025
2025
Q2
Q2 2025 Earnings
8-KAug 6, 2025
0001438133-25-000155
tndm-202508060001438133FALSE00014381332025-04-302025-04-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025
Tandem Diabetes Care, Inc. (Exact name of registrant as specified in its charter)
Delaware001-3618920-4327508 (State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.) 12400 High Bluff Drive92130 San Diego California (Zip Code) (Address of principal executive offices)
Registrant’s telephone number, including area code: (858) 366-6900 N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of Each ClassTrading SymbolName of Each Exchange on Which Registered Common Stock, par value $0.001 per shareTNDMNASDAQ Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On June 30, 2025, we issued a press release reporting our financial results for the quarter ended June 30, 2025. This press release has been furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
The information under this Item 2.02 and Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
Number Description
99.1Press release of Tandem Diabetes Care, Inc. dated June 30, 2025.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Tandem Diabetes Care, Inc.
By:/s/ SHANNON M. HANSEN Shannon M. Hansen Executive Vice President, Chief Legal, Privacy & Compliance Officer and Secretary
Date: August 6, 2025 3
Latest Tandem Diabetes Care Inc. News
TNDM Breaking Stock News: Dive into TNDM Ticker-Specific Updates for Smart Investing
The Fly
Micron downgraded, Five Below upgraded: Wall Street's top analyst calls
📈
AI Sentiment
Highly Positive
8/10
MT Newswires
Truist Upgrades Tandem Diabetes Care to Buy From Hold, Raises Price Target to $35 From $27
📊
AI Sentiment
Positive
6/10
Zacks
Strength Seen in Tandem Diabetes Care (TNDM): Can Its 9.1% Jump Turn into More Strength?
📊
AI Sentiment
Positive
7/10
MT Newswires
Tandem Diabetes Care Shares Rise After Piper Sandler Upgrade
📈
AI Sentiment
Highly Positive
8/10
Compare TNDM vs Leading Stocks
See how TNDM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TNDM Tandem Diabetes Care Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.